Yes, ivabradine is often prescribed alongside beta-blockers to achieve additional heart-rate reduction when beta-blockade alone is insufficient. The combination requires careful monitoring for excessive bradycardia.
Transient visual phenomena (phosphenes) are a known side effect. They usually resolve with continued therapy. If the symptoms persist or worsen, inform your prescriber.
Both strengths contain the same active ingredient; the 7.5 mg tablet simply delivers a higher dose. In the UK, the 5 mg tablet is the most commonly prescribed strength.
Yes, but keep the medication in its original labelled container, carry a copy of the prescription, and be aware that some countries may require additional documentation for heart-rate-modifying drugs.
Ivabradine primarily lowers heart rate and has minimal direct effect on systolic or diastolic blood pressure. However, reductions in heart rate can indirectly improve cardiac efficiency, sometimes leading to modest blood-pressure changes.
No specific food interactions are reported. The pill may be taken with or without meals, but maintaining a consistent routine helps stabilize drug absorption.
It is supplied as a round, white 5 mg pill with the imprint “PROCORALAN 5 mg”. The packaging includes the MHRA batch number and expiry date.
Ivabradine is not listed on the World Anti-Doping Agency (WADA) prohibited list, but athletes should disclose all medications to their medical team to avoid inadvertent rule breaches.
Patients often report reduced angina frequency within 2-4 weeks of consistent dosing, provided the heart-rate target is achieved.
Ivabradine is not primarily cleared by the kidneys, so mild-to-moderate renal impairment does not usually require dose adjustment. Severe renal disease should be evaluated individually by a clinician.
Procoralan is a prescription heart medication marketed in the United Kingdom under the brand name Procoralan. Its active ingredient is ivabradine, a selective inhibitor of the cardiac “funny” (If) current. The product is supplied as a 5 mg pill and is regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). It is manufactured by Takeda Pharmaceuticals (originally Shire). Procoralan belongs to the therapeutic area Heart & Blood Pressure and is used to manage certain chronic heart conditions.
Ivabradine reduces the heart’s resting rate by specifically blocking the If channels in the sino-atrial (SA) node. These channels normally generate spontaneous electrical activity that sets the heart’s rhythm. By slowing the influx of sodium and potassium ions through the If pathway, ivabradine decreases the number of impulses that initiate each heartbeat.
Because ivabradine acts only on heart-rate control, it does not significantly affect myocardial contractility or blood pressure, making it a useful adjunct when beta-blockers are insufficient or contraindicated.
These indications are approved by the MHRA and are reflected in the UK product label.
Ivabradine has been investigated for inappropriate sinus tachycardia and certain forms of post-cardiac-surgery tachyarrhythmia. Clinical studies suggest a modest reduction in heart rate and symptom burden, but the drug has not received regulatory approval for these indications in the UK.
Disclaimer: Off-label use requires medical supervision and individualized risk assessment.
This article provides educational information about Procoralan and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
